Search results
Results From The WOW.Com Content Network
Fenticonazole is an imidazole antifungal drug, used locally as the nitrate in the treatment of vulvovaginal candidiasis. It is active against a range of organisms including dermatophyte pathogens, Malassezia furfur, and Candida albicans.
Clotrimazole is usually used five times daily for 14 days for oral thrush, twice daily for 2 to 8 weeks for skin infections, and once daily for 3 or 7 days for vaginal infections. [ 10 ] Clotrimazole may be compounded with a glucocorticoid , such as betamethasone , in a topical cream for the treatment of tinea corporis (ringworm), tinea cruris ...
Nystatin is used topically for the treatment of Candida infections of the skin and mucous membranes. [9] Oral candidiasis (Oral Thrush) Nystatin is commonly used in treatment of lesions of the mouth caused by oral candidiasis. The drug can be formulated in pastilles or suspensions and is directly applied to the affected area. After application ...
Antifungal resistance to drugs in the azole class tends to occur gradually over the course of prolonged drug therapy, resulting in clinical failure in immunocompromised patients (e.g., patients with advanced HIV receiving treatment for thrush or esophageal Candida infection).
Some fungi (e.g. Candida krusei and fluconazole) exhibit intrinsic resistance to certain antifungal drugs or classes, whereas some species develop antifungal resistance to external pressures. Antifungal resistance is a One Health concern, driven by multiple extrinsic factors, including extensive fungicidal use, overuse of clinical antifungals ...
It is active against some fungi including Candida albicans. Candicidin is administered intravaginally in the treatment of vulvovaginal candidiasis. [1] This bioactive compound was named candicidin, because of its high activity on Candida albicans. [2]
While Candida albicans is the most common yeast species associated with vaginal thrush, infection by other types of yeast can produce similar symptoms. A Hungarian study of 370 patients with confirmed vaginal yeast infections identified the following types of infection: [18] Candida albicans: 85.7%; Non-albicans Candida (8 species): 13.2%
Ibrexafungerp is indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC). [1] [4]Ibrexafungerp is currently undergoing late-stage clinical trials for an intravenous formulation for the treatment of various fungal diseases, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species.